News Releases

HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022

March 17, 2022 at 7:00 AM EDT

NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2021 financial results before the market opens on Thursday, March 24, 2022. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update.

Conference Call & Webcast:

Date:March 24, 2022
Time:8:30 AM ET
USA Dial In:+1 877 870 9135
UK Dial In:0800 279 6619
Austria Dial In:+43 (0)1 928 4090
Conference ID:1868118

The webcast and the presentation will also be available within the Investors & Media section of HOOKIPA’s website at

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at

For further information, please contact:
Instinctif PartnersMatt Beck
hookipa@instinctif.comExecutive Director - Investor Relations
+44 (0)20 7457